PDCD1 and gastric cancer: PD-1 and PD-1 ligand (PD-L1) are highly expressed in EBV-LPD pathological tissues (15–17), and PD-1 inhibitors have been shown to be effective against EBV+ gastric cancer (18) and refractory/relapse ENKTL (19–21).